OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced Shionogi Inc., a New Jersey-based ...
A recent study published in JAMA Network Open evaluated the cost-effectiveness of monoclonal antibodies (mAbs) as pre-exposure prophylaxis (PrEP) for coronavirus disease 2019 (COVID-19). Study: Health ...
A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, ...
HIV pre-exposure prophylaxis (PrEP) is a prevention strategy which includes the regular or event-driven use of antiretroviral medication to prevent HIV infection in adults. Several clinical trials ...
Lenacapavir is a long-acting injectable Pre-Exposure Prophylaxis (PrEP) option administered once every six months ...
HIV-1 infection remains a major public health problem, with an estimated 38.4 million people living with HIV and 1.5 million new HIV infections reported worldwide in 2021. The risk of HIV infection ...
Prefer Newsweek on Google to see more of our trusted coverage when you search. A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral ...
Oral HIV pre-exposure prophylaxis (PrEP) is highly effective for preventing HIV. Several different developments in the US either threaten to increase or promise to decrease PrEP out-of-pocket costs ...
HIV pre-exposure prophylaxis (PrEP) is an effective and safe intervention for individuals with behaviors that are considered high risk for acquiring HIV infection. Despite the success of this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results